Hydrocodone Bitartrate
FDA-approved product (capsule, extended release, oral), marketed as Hydrocodone Bitartrate, Hysingla Er, Vantrela Er and 1 more.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 2 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Cough
- Drug dependence
- Pain
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Natural opium alkaloids; Opium alkaloids and derivatives
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and K. pneumoniae. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA44.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli36.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae46.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- M. tuberculosis36.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Hydrocodone Bitartrate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- UrsodiolExisting use: Biliary liver cirrhosis, Primary biliary cirrhosis69.2% AI-predicted activityagainst MRSA50+ registered studies
- OlaparibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 9 more69.2% AI-predicted activityagainst MRSA50+ registered studies
- Ganirelix AcetateExisting use: Female infertility, Positive regulation of ovulation, Reproductive Techniques, Assisted69.1% AI-predicted activityagainst MRSA50+ registered studies
- DanicopanExisting use: Acquired paroxysmal nocturnal hemoglobinuria, Hemoglobinuria, Paroxysmal, Hemolysis68.7% AI-predicted activityagainst MRSA30 registered studies
- Simeprevir SodiumExisting use: Chronic hepatitis C virus infection68.6% AI-predicted activityagainst MRSANo documented evidence found
- Lanreotide AcetateExisting use: Acromegaly, Carcinoid syndrome68.3% AI-predicted activityagainst MRSA50+ registered studies
- Cholic AcidExisting use: Abnormality of the gastrointestinal tract, Inborn errors of metabolism, Liver disease and 1 more68.0% AI-predicted activityagainst MRSA50+ registered studies
- EptifibatideExisting use: Acute coronary syndrome, Acute myocardial infarction, Intermediate coronary syndrome and 2 more67.8% AI-predicted activityagainst MRSA35 registered studies
- AbarelixExisting use: Neoplasm67.7% AI-predicted activityagainst MRSA5 registered studies
- EverolimusExisting use: Adenoma sebaceum, Anaplastic astrocytoma, Angiomyolipoma and 18 more67.5% AI-predicted activityagainst MRSA50+ registered studies
- Paliperidone PalmitateExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more67.3% AI-predicted activityagainst MRSA50+ registered studies
- PaliperidoneExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more67.2% AI-predicted activityagainst MRSA50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Role of Pregabalin in Treatment of Post-Op Pain in Fracture Patients
NCT00583869 · start 2007-05
Registered record
- Registry ID
- NCT00583869
- Conditions
- Post-operative Pain
- Interventions
- Placebo; Pregabalin; Pregabalin
- Study type
- INTERVENTIONAL
- Phase
- Early phase 1
- Registry status
- Completed
- Start
- 2007-05
- Completion
- 2009-08
- Enrolment
- 86
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPost-operative PainInterventionPlacebo; Pregabalin; PregabalinPhaseEarly phase 1Registry statusCompletedTrial Comparing Intravenous and Oral Moderate Sedation for First Trimester Surgical Abortions
NCT01011634 · start 2007-05
Registered record
- Registry ID
- NCT01011634
- Conditions
- Undesired Intrauterine Pregnancy; First Trimester Pregnancy
- Interventions
- Intravenous moderate sedation versus oral medication
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Terminated
- Start
- 2007-05
- Completion
- 2008-11
- Enrolment
- 18
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionUndesired Intrauterine Pregnancy; First Trimester PregnancyInterventionIntravenous moderate sedation versus oral medicationPhasePhase 4Registry statusTerminatedA Comparison of the Addiction Liability of Hydrocodone and Sustained Release Morphine
NCT00314340 · start 2005-11
Registered record
- Registry ID
- NCT00314340
- Conditions
- Chronic Pain
- Interventions
- Markers of Abuse Liability, Neuropsych Testing, and Cue Reactivity; ER Morphine; hydrocodone plus acetaminophen; placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2005-11
- Completion
- 2008-04
- Enrolment
- 12
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionChronic PainInterventionMarkers of Abuse Liability, Neuropsych Testing, and Cue Reactivity; ER Morphine; hydrocodone plus acetaminophen; placeboPhasePhase 4Registry statusCompletedA Study Comparing the Analgesic Activity of Extended Release Hydrocodone/Acetaminophen (Vicodin® CR) and Placebo in Subjects With Pain Following Bunionectomy Surgery
NCT00404391 · start 2003-10
Registered record
- Registry ID
- NCT00404391
- Conditions
- Pain
- Interventions
- Hydrocodone/Acetaminophen Extended Release; Hydrocodone/Acetaminophen Extended Release; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2003-10
- Completion
- 2004-03
- Enrolment
- 210
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPainInterventionHydrocodone/Acetaminophen Extended Release; Hydrocodone/Acetaminophen Extended Release; PlaceboPhasePhase 2Registry statusCompletedA Multicenter Active Comparator Study of HC-ER in Adults Following Bunionectomy Surgery
NCT02197156 · start 2002-08
Registered record
- Registry ID
- NCT02197156
- Conditions
- Postoperative Pain
- Interventions
- 10 mg HC-ER; 20 mg HC-ER; 30 mg HC-ER; 40 mg HC-ER; 10 mg HC / 325 mg APAP; Matching Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2002-08
- Completion
- 2003-02
- Enrolment
- 241
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPostoperative PainIntervention10 mg HC-ER; 20 mg HC-ER; 30 mg HC-ER; 40 mg HC-ER +2 morePhasePhase 2Registry statusCompleted